[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380707-105":59,"doc-detail-380707-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","recent-updates-in-venetoclax-combination-therapies-in-pediatric-hematological-malignancies","Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies","","Venetoclax, a BCL-2 inhibitor, selectively restores apoptotic potential in cancer cells and has improved outcomes in adults with AML, CLL, and MM when used in combination with immunotherapy, targeted therapies, or lower-intensity regimens such as HMAs or low-dose cytarabine. Its clinical benefit in pediatric hematology remains less clear. Emerging preclinical and clinical trials indicate that venetoclax-based combination treatment in many younger patients can be well tolerated with an adult-like safety profile, although severe infections may still occur. Current studies focus on evaluating venetoclax activity in primary and refractory acute leukemias combined with standard and high-dose chemotherapy, aiming to define an optimal pediatric regimen and clarify long-term effects.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/recent-updates-in-venetoclax-combination-therapies-in-pediatric-hematological-malignancies/380707/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/recent-updates-in-venetoclax-combination-therapies-in-pediatric-hematological-malignancies/380707.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-25","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is venetoclax, and why is it used in combination therapies?","Question",{"text":112,"@type":113},"Venetoclax is a BCL-2 inhibitor that restores the apoptotic potential of cancerous cells. It is combined with immunotherapy, targeted therapies, and lower-intensity regimens to improve outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is venetoclax safety described for pediatric patients?",{"text":117,"@type":113},"Newer findings suggest venetoclax combinations can be well tolerated in many pediatric patients. The safety profile is similar to adults, but severe infections can still occur.",{"name":119,"@type":110,"acceptedAnswer":120},"What do the current studies aim to determine for pediatric leukemia treatment?",{"text":121,"@type":113},"Studies aim to evaluate venetoclax activity in primary and refractory acute leukemias when used with standard and high-dose chemotherapy. They also seek to identify optimal venetoclax-based regimens and assess long-term patient outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380707,1790342347,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Review  \nRecent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies  \nMaria Le´sniak 1, Justyna Lipniarska 1, Patrycja Majka 1, Monika Lejman 2,† and Joanna Zawitkowska 3, *,†  \nCitation: Le´sniak, M.; Lipniarska, J.; Majka, P.; Lejman, M.; Zawitkowska, J. Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies. Int. J. Mol. Sci. 2023, 24, 16708. [https://](https://)[ ](https://)[doi.org/10.3390/ijms242316708](doi.org/10.3390/ijms242316708)  \nAcademic Editor: Akiyoshi Takami  \nReceived: 27 October 2023  \nRevised: 16 November 2023  \nAccepted: 22 November 2023  \nPublished: 24 November 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland; [marialesniak68@gmail.com](marialesniak68@gmail.com) (M.L.); [justyna.lipniarska@gmail.com](justyna.lipniarska@gmail.com) (J.L.); [patrycja_majka@wp.pl](patrycja_majka@wp.pl) (P.M.)  \n2 Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland; [monika.lejman@umlub.pl](monika.lejman@umlub.pl)  \n3 Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland  \n* [Correspondence: joannazawitkowska@umlub.pl](Correspondence: joannazawitkowska@umlub.pl)[ ](Correspondence: joannazawitkowska@umlub.pl)† These authors contributed equally to this work.  \nAbstract: Venetoclax is a strongly effective B-cell lymphoma-2 inhibitor (BCL-2) with an ability to selectively restore the apoptotic potential of cancerous cells. It has been proven that in combination with immunotherapy, targeted therapies, and lower-intensity therapies such as hypomethylating agents (HMAs) or low-dose cytarabine (LDAC), the drug can improve overall outcomes for adult patients with acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), amongst other hematological malignancies, but its benefit in pediatric hematology remains unclear. With a number of preclinical and clinical trials emerging, the newest findings suggest that in many cases of younger patients, venetoclax combination treatment can be well-tolerated, with a safety profile similar to that in adults, despite often leading to severe infections. Studies aim to determine the activity of BCL-2 inhibitor in the treatment of both primary and refractory acute leukemias in combination with standard and high-dose chemotherapy. Although more research is required to identify the optimal venetoclax-based regimen for the pediatric population and its longterm effects on patients' outcomes, it can become a potential therapeutic agent for pediatric oncology.  \nKeywords: venetoclax; Bcl-2 inhibitors; pediatric hematology; leukemia; treatment  \n1. Introduction  \n1.1. Apoptosis  \nApoptosis is a major form of programmed cell death, which is very important for the development and functioning of multi-cellular organisms. It regulates cell number, the removal of structures, and tissue sculpting and also protects against pathogens [1] . Apoptosis deregulation can lead to many diseases—cancer, autoimmune diseases, viral infections, or neurodegenerative disorders [2] .  \nCaspases play a key role in the mechanism of apoptosis as they are both the initiators (caspase-8, -9, and-10) and executioners (caspase-3, -6, and-7) of the process. There are two main pathways by which caspases can be activated—the intrinsic (mitochondrial) pathway, initiated by microenvironmental disturbances, and the extrinsic (death receptor) pathway, activated by disturbances of t","cbCaim4D0WIqm4Pe","https://ap.wps.com/l/cbCaim4D0WIqm4Pe","pdf",792152,26,"English","# Introduction\n## Apoptosis\n## B-Cell Lymphoma 2 (Bcl-2) Protein Family","[{\"question\":\"What is venetoclax, and why is it used in combination therapies?\",\"answer\":\"Venetoclax is a BCL-2 inhibitor that restores the apoptotic potential of cancerous cells. It is combined with immunotherapy, targeted therapies, and lower-intensity regimens to improve outcomes.\"},{\"question\":\"How is venetoclax safety described for pediatric patients?\",\"answer\":\"Newer findings suggest venetoclax combinations can be well tolerated in many pediatric patients. The safety profile is similar to adults, but severe infections can still occur.\"},{\"question\":\"What do the current studies aim to determine for pediatric leukemia treatment?\",\"answer\":\"Studies aim to evaluate venetoclax activity in primary and refractory acute leukemias when used with standard and high-dose chemotherapy. They also seek to identify optimal venetoclax-based regimens and assess long-term patient outcomes.\"}]","Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies | PDF",1790241398,66]